CXCR4 and E-selectin antagonist may modify the composition of osteolytic behavior and this may be impacting bone tumor growth in the presence or absence of DTX and to be responsible for apparently “off-target effects”. The gene discussed is CXCR4; the disease is bone neoplasm.